Multiple city supervision departments joining the pharmaceutical anti-corruption storm: publicly soliciting clues on commercial bribery in the pharmaceutical industry. Name | medical | enterprise | promotion | commercial | field | bribery | pharmaceutical
On August 18th, the Market Supervision Administration of Heilongjiang Province announced that it will collect clues on commercial bribery issues in the pharmaceutical industry from August this year to June next year.
The solicitation content includes: pharmaceutical production and operation enterprises providing kickbacks to medical institutions or their internal departments and employees under various names or forms, such as borrowing consulting fees, lecture fees, promotion fees, etc; The illegal behavior of pharmaceutical production and operation enterprises using academic conferences, scientific research collaborations, academic support, and donations to transfer benefits. According to the Market Supervision Administration of Heilongjiang Province, this move is aimed at strengthening the supervision of behavior that disrupts market order in the pharmaceutical industry, cracking down on commercial bribery in the pharmaceutical industry, and maintaining a fair competitive market environment in the pharmaceutical industry.
Public information shows that in this round of anti-corruption in the pharmaceutical industry, market regulatory authorities in multiple regions have successively taken measures.
Among them, the Inner Mongolia Autonomous Region Market Supervision Administration stated on August 18th that it publicly solicits clues on commercial bribery in the pharmaceutical industry, looks forward to the joint participation of the whole society, and welcomes complaints, reports, or clues from society and people from all walks of life. The specific solicitation content includes:
The act of pharmaceutical production and operation enterprises providing benefits and maintaining relationships to medical institution staff under the guise of consulting fees, promotion fees, etc. for departmental lectures; Pharmaceutical production and operation enterprises engage in commercial bribery by bundling and selling drugs and consumables in the form of false donations, scientific research cooperation, experimental promotion, etc; Pharmaceutical production and operation enterprises engage in commercial bribery in the fields of drug and medical equipment procurement, engineering construction, and research funding; Other commercial bribery behaviors in the pharmaceutical industry.
The clues collected by the Market Supervision Bureau of Nanchang City, Jiangxi Province regarding suspected commercial bribery and illegal activities in the pharmaceutical industry include:
1. Pharmaceutical enterprises engage in illegal and irregular activities such as using bills, fabricating business matters, and using empty or fictitious activities of pharmaceutical promotion companies to embezzle funds in the circulation process, and using the embezzled funds for commercial bribery. 2. The illegal and irregular behavior of pharmaceutical companies using funds in the production process for kickbacks on pharmaceutical consumables and equipment, as well as commercial bribery. 3. Medical enterprises engage in illegal and irregular activities in the fields of equipment procurement, engineering construction, research funding, etc. by using sponsorship fees, consulting fees, lecture fees, promotion fees, scientific research cooperation, academic promotion, etc. 4. Pharmaceutical enterprises engage in bribery of other units or individuals through financial or other means during the sales process of pharmaceutical products.
In addition, the Market Supervision Administration of Datong City, Shanxi Province has also combined its functional tasks to disclose clues and reporting channels for commercial bribery in the pharmaceutical industry. The specific situation includes the behavior of pharmaceutical production, operation enterprises or marketing personnel paying medical institutions or related personnel in cash and physical goods under the names of "commission fees", "prescription fees", "new drug promotion fees", "clinical observation fees", etc. during the clinical diagnosis and treatment process; The act of pharmaceutical production and operation enterprises providing domestic and overseas tourism to medical institution staff in the name of "training sessions", "seminars", "inspections", and other benefits other than providing financial benefits to medical institutions or related personnel.